Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, t...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Nan Zhang, Xu Yang, Mingjian Piao, Ziyu Xun, Yunchao Wang, Cong Ning, Xinmu Zhang, Longhao Zhang, Yanyu Wang, Shanshan Wang, Jiashuo Chao, Zhenhui Lu, Xiaobo Yang, Hanping Wang, Haitao Zhao
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2024-02-01
Saila:	Biomarker Research
Gaiak:	Hepatocellular carcinoma Programmed death-1 Programmed death ligand 1 Immune checkpoint inhibitors Biomarker
Sarrera elektronikoa:	https://doi.org/10.1186/s40364-023-00535-z
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!